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Abstract 
As we enter the twenty-first century, several therapies based on using nanoparticles (NPs) 
ranging in size 1 – 1000 nm have been successfully brought to the clinic to treat cancer, pain 
and infectious diseases. These therapies bring together the ability of NPs to target the delivery 
of drugs more precisely, to improve solubility, to prevent degradation, to improve their 
therapeutic index and to reduce the immune response. NPs come in all shapes and sizes, 
designed specifically for biomedical applications such as solid lipid polymers, liposomes, 
dendrimers, nanogels, and quantum dots. These NPs offer many attractive characteristics such 
as biological stability and biocompatibility can incorporate different biological or drug 
molecules. Among the major challenges in human disease therapy in neurological diseases 
through to cancer is the development of nanomaterials that are able to be effective against the 
disease. In the case of neurodegeneration, one of the most difficult areas to penetrate for drug 
discovery in the body is the central nervous system, protected by the blood-brain-barrier. 
Whilst in the case of cancer, the biggest problem is how to specifically target the tumor with 
sufficient drug without causing side effects or inducing resistance. A new generation of 
intelligent NPs are emerging in the treatment of human disease such as neurological disorders 
and cancer. The use of natural alternative therapy is an encouraging idea in drug discovery. 
To this end as we gain more knowledge into the biological function of exosomes, this will 
allow us to harness their potential as natural NPs in future therapeutics. 
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Introduction 
Nanoparticle (NP) research is a field of growing scientific interest due to the different 
potential uses within the field of biomedicine [1, 2]. From the first discoveries back in 1965 
until the last 25 years has seen a massive exponential growth in the nanotechnology field 
(Figure 1). NPs in nanotechnology are termed as small units that can act by themselves 
facilitating both their transport and properties. The entity of NPs with therapeutic potential are 
usually comprised of small-molecule drugs, proteins and nucleic acids assembled with for 
example, lipids and polymers (Fig. 2). At the present state of the art, numerous scientists 
throughout the world are involved in the study of vesicles and other colloidal structures as 
carriers for drug delivery. Improvements to pharmacokinetics and pharmacodynamics, these 
particles are designed to have enhanced anticancer effects allowing more specific targeting to 
tumor tissues. The efficacy of these NPs depends upon integral properties such as surface 
properties and size. Here, in this review, we discuss the recent published investigations on the 
important role that NPs both natural and synthetic play in physiological and pathological 
pathways such as in neurodegeneration to cancer through communication and 
microenvironment control. In addition, we discuss how these NPs have been utilised in human 
therapy and their future relevance in diagnosis and therapeutics.  
 
Nanoparticles 
NPs can range in size from 100 to 2500 nm, smallest particles between 1 and 100 nm. NPs 
that have a therapeutic value are used as a vehicle carrying small molecules such as drugs, 
peptides, proteins, and nucleic acids. There are several types of particles (nanofibres, 
nanotubes, NPs, nanogels) that can be assembled with a therapeutic entity (Fig. 2A). The NPs 
physiochemical properties such as shape, surface charge, size, hydrophobicity etc. can all 
affect the absoprtion and/or correct targeting to certain areas in the body such as certain 
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tissues and these properties are necessary to consider in the NP design (Fig. 2B) [3]. The 
properties of NPs may or may not depend upon the size of the fine particles. Thus, individual 
molecules could be the size of ultrafine particles are not classed as NPs. We will discuss 
herein the vehicles used for drug delivery that have been developed from solid lipid NPs to 
nanogels. 
 
Types of nanoparticles-vesicles 
 
Solid lipid nanoparticles (SLNs) are colloidal carriers, spherical in structure (50 to 
1000 nm) containing physiologically tolerated lipid components such as fatty acids, waxes, or 
glycerides, with emulsifiers such as polyoxyethylene ethers, polyvinyl alcohol, phospholipids, 
bile salts, or Tween®, with solid shape at room temperature (Fig. 2, Table 1) [4]. The major 
advantages of SLNs are that the surface is hydrophilic-coated, thus reducing toxicity of these 
NPs as they are not readily absorbed by cells of the reticuloendothelial system (RES) cells and 
therefore can bypass the liver and spleen [5]; are easily manufactured since they have a high 
and improved drug content, good biodegradation [6], increased bioavailability of encapsulated 
compounds, and offer very high long-term stability [7]. In addition, SLNs have contributed to 
major advances in the development of oral bioavailability of poor soluble drugs [8] such as 
curcumin for treating a number of human diseases including neurodegenerative diseases 
(ND), cancer and liver disease [9-11]. 
 
Liposomes/micelles are spherical micro- or nano-structures consisting of one or more 
bilayer with liquid in the core and between the lipid bilayers (Fig. 2). Since the first discovery 
of liposomes by Alex Bangham in 1965, liposomes have been of upmost interest to the 
pharmaceutical industry and extensively studied as drug carriers [12, 13]. In the last 30 years 
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they have had many clinical uses and have been used to change pharmacokinetics, 
biodistribution, and cellular trafficking of drugs, nucleic acids, and proteins. There are 
different types of liposomes that vary in size and composition. Multilamellar vesicles: with a 
size range of 500 to 5,000 nm and have multiple bilayers. Large unilamellar vesicles: with a 
size range of 200 to 800 nm. Small unilamellar vesicles: approximately 100 nm in size and 
consist of a single bilayer. Long-circulating liposomes: these are modified liposomes (can 
have specific polymers at their surface) increasing their lifetime in the blood circulation than 
conventional non-modified liposomes. Immunoliposomes: these have antibodies grafted to 
their surface facilitating them to accumulate in the area within a region of the body where the 
attached antibody can be recognized. 
 
 Polymeric NPs 
Polymeric NPs (PNPs) are defined as solid, colloidal particles between 10 – 1000 nm in size 
[14] (Fig. 2). The PNPs is a general name used for any polymer nanoparticle, normally for 
nanocapsules and nanospheres. Nanocapsules have a solid shell, are spherical in shape and 
have a liquid cavity. Nanospheres are spherical solid particles and the surface is used to 
adsorb molecules at the surface or captured within the particle. PNPs are used mainly as drug 
carriers offering controlled delivery and good biodegradation [15]. 
 
 Gold NPs 
Colloidal gold has origins from ancient times as a method for glass staining. In 1857, Michael 
Faraday first reported the optical properties and the quantum size effect of gold nanoparticles 
(AuNPs) [16]. Since these first works, AuNPs have generated immense interest and in the last 
decades many applications of using these particles in nanotechnology have been developed 
[17, 18]. AuNPs are a suspension of gold particles with a size between 3 to 200 nm (Fig. 2). 
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AuNPs have great optical and electronic properties, highly stabile, biologically compatible, 
and reproducible morphology [19]. 
 
 Quantum dots 
Quantum dots (QDs) were first investigated in 1983 by Rossetti and colleagues [20]. QDs are 
the smallest of the NPs between 3 to 30 nm, composed of semiconductor materials 
synthesized as core–shell or alloy nanocrystalline colloids from II-VI groups (for example, 
CdSe) or III-V (for example, InP) of the periodic table [21] (Fig. 2). The size of the QD 
correlates with electronic excitation energy i.e. smaller QDs have a higher energy than larger 
ones. As a result, the oscillator strength is confined to a few transitions providing finely tuned 
phototonic and electronic quantum properties [22]. QDs are fairly flexible particles offering 
great biological function and are highly stable [23]. They have a multiple roles in 
nanotechnology not only in bioimaging and biosensing but also in the diagnosis and therapy 
of disease [24]. 
 
 Carbon nanotubes 
In the early 1990s, after the discovery of a third allotropic form of carbon fullerene, Sumio 
Iijima found a new cylindrical structure of carbon fullerene and hence named these carbon 
nanotubes (CNTs) [25]. CNTs are composed of rolled graphene sheets as open cylinder or 
capped ends with a size in diameter by 0.4-3 nm and length by 20-1000 nm [26] (Fig. 2). 
There are two types of CNTs depending upon the number of sheets rolled in the cylinders, the 
single-walled or multi-walled CNTs. Single-walled CNTs are made up of a one graphene 
layer held together by Van der Waals forces giving more flexibility whilst the multiwalled 
CNTs have several layers of coaxial cylinders around a single graphene sheet giving less 
flexibility and resulting in structural defects. For a number of years CNTs have been used in 
Wilson et. al. 2014 
Review: ‘The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer’ 
 
6 
 
various commercial products such as rechargeable batteries to water filters [27]. Research 
using CNTs as carriers of biomolecules such as DNA and proteins is ongoing and are still not 
available as clinical medicines. However, CNT nanotechnology is attracting attention in the 
industry as ideal candidates for drug delivery. Several groups have developed potential 
applications using CNTs to specifically target tumor drug delivery, for example in the 
treatment of leukemia [28], liver [29], and bladder cancer [30]. The potential toxicity elicited 
using CNTs remains a problem and has been attributed to their physical properties but can be 
avoided by surface-grafting biomacromolecules or polymers [31]. 
 
 Dendrimers 
Dendrimers are macromolecules comprising of symmetrically arranged branches ascending 
from a multi-functional core with a size range between 2 to 10 nm (Fig. 2). Tomalia and 
colleagues described the first synthesis of dendrimers back in 1985 which were referred to as 
“starburst polymers.” Dendrimers can encapsulate active drugs and deliver these active drugs 
to target tissues. Also, dendrimers can present targeting ligands at their surface aiding correct 
delivery to the target tissue. [32]. Polyamidoamine dendrimers are the most well-characterized 
dendrimer family composed of a diamine core reacted with methyl acrylate and 
ethylenediamine to give consistent radial concentric layers. 
 
 Iron oxide NPs 
Iron oxide nanoparticles (IONPs) comprise of magnetite (Fe3O4) or maghemite (γ-Fe2O3) in 
the range size of 5 to 200 nm (Fig. 2). IONPs represent an important class of NPs that are 
backing the current revolution in nanotechnology and nanomedicine [33-35]. Owing to their 
exclusive physical properties such as their high surface area to volume ratio and super 
magnetism (whilst Cobalt and Nickel are highly magnetic, the disadvantages are they are 
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fairly toxic and easily oxidized), are useful features for medical approaches such as magnetic 
resonance imaging (MRI), tissue engineering, bioseparation, and drug/gene delivery [35]. 
Subsequently, to reduce toxicity the hydrophobic IONPs can be coated with different 
inorganic materials such as phospholipids, amphiphilic polymers or silica, thus improving 
their solubility and biocompatibility in vivo.  
 
Cerium oxide NPs 
Cerium oxide nanoparticles (CONPs) are composed of a cerium core with an external oxygen 
lattice. These NPs have been used frequently for many biological and engineering 
applications, for example as solar cells [36], in high-temperature oxidation protection 
materials [37], in solid-oxide fuel cells [38], and catalytic materials [39]. CONPs are of 
particular interest in nanomedicine as they have shown the capacity for a number of 
approaches [40]. The cell or tissue conditions are believed to be important in the role of 
determining redox activity, since CONPs have additionally been observed to present a number 
of antioxidant reactivity such as catalase mimetric activity [41], superoxide dismutase (SOD) 
activity [42], hydroxyl radical scavenging [43], and nitric oxide radical scavenging [44]. In 
addition, CONPs have been shown to possess oxidant behavior [45] and these activities 
(oxidant or antioxidant) are believed to be driven by the pH levels [46, 47]. 
 
 Mesoporous silica NPs (MSNPs) 
MSNPs were originally discovered in 1992 by the Mobile Oil Corporation. In recent years, 
they are emerging as a promising candidate for drug delivery in the nanotechnology field. The 
MSNPs have a size of 50 to 200 nm and are surface-grafted with polyethyleneimine (PEI) or 
PEI- polyethylene glycol (PEG) or polyamidoamine. Modifying the surface of MSNPs offers 
both the benefits of loading small interfering RNA (siRNA) and improved uptake and 
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delivery to cells. The most common types are Mobil Composition of Matter-41 and Santa 
Barbara Amorphous-15 also known as MCM-41 and SBA-15 respectively [48]. The physical 
properties of these NPs are ideal for the purpose of drug loading, controlled drug release and 
delivery, and multi-functionalization [49, 50]. MSNPs could be used for the delivery of drugs 
but also for a number of other applications including intracellular controlled catalysis and as a 
biosensor in tumor imaging. 
 
 Nano-hydroxyapatite (n-HA) 
Hydroxyapatite (HA) is a bio mineral composed of calcium and phosphate, represented by the 
chemical formula (Ca10(PO4)6(OH)). It is the main organic component of human hard tissues 
such as tooth and bone. In the past years, HA has been of particular interest to the medical 
field due its application in prosthetics. The proportion of the aging population is increasing 
and as an effect the number of people presenting with bone illnesses such as fractures due to 
osteoporosis and patients bedridden due to apoplexy are on the increase [51]. HA can be 
manufactured in different forms from a composite ceramic to powder form depending upon its 
application. nHA with the size of >100nm has been developed over the past years. Several 
groups have shown that nHA NPs have minimal effects on healthy cells whilst at the same 
time inhibit specifically the cellular proliferation of cancer cells, such as liver and glioma cells 
[52-54]. nHA NPs coated with a fluorescent dye are great carriers for applications such as 
imaging or for photodynamic therapy. The development of future technologies offers many 
interesting avenues of new research including the development of ceramic particles 
incorporating drugs such as doxorubicin [55] that are required to be slow-released over 
several days or months. The time of release could be controlled by the CaP composite having 
varying times of degradation. 
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Nanogels 
Nanogels are nanosized particles with a size range between 20 to 200 nm, are formed by 
physical or chemical cross-linked polymer networks that are able to swell upon contact with 
solvent. The use of “nanogel” (NanoGel™) was first described to explain the cross-linked 
bifunctional networks of a polymer (polyion and a non-ionic polymer) in the delivery of 
polynucleotides (cross-linked PEG-cl-PEI or PEI and PEG) [56]. Nanogels have pores that 
can be filled with small molecule compounds and biomacromolecules [57]. Their physical 
properties can be controlled, such as swelling, degradation, and chemical functionality which 
all are important in delivering drugs in a controlled, sustained and targetable way. 
 
Administration routes for therapy with NPs 
Given their modularity and the possibility to build/customize NPs for the drug delivery, NPs 
are very promising for therapeutics especially owing to that they permit control of drug 
release and to increase their bioavailability with a low immunogenicity. Furthermore, by 
dedicated engineering it is possible to target specifically the lesion site limiting the side 
effects of highly toxic compounds. Besides, an important concern to take account is how to 
bring these drug carriers into the organism to facilitate the targeting of the affected organ, 
maximizing its bioavailability and limiting the drug side effects. As an example, the intranasal 
delivery is studied for antibiotherapy against tuberculosis with streptomycin, to limit its 
ototoxicity and nephrotoxicity and increase its bioavailability [58]. By consequence, the 
choice of the administration route is crucial [59]. Numerous routes were described in the 
literature concerning NP administration (Fig. 3): 
- parenteral (intravenous, intramuscular or subcutaneous) [60]; 
- oral [61] 
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- rectal [62] 
- transdermal [63] 
- pulmonary [64, 65] 
- nasal [66, 67] 
- ocular  [68]…. 
Amongst these multiple choices, the first point to consider is the anatomical localization and 
particularities linked to the targeted defect choosing between a local or a systemic delivery. In 
this way, the nasal route is of great interest for drug delivery directly to the brain, bypassing 
the BBB (blood-brain-barrier) [69]. The oral route is the most convenient but between the 
mouth and the intestinal mucosa, the difficult point for the NPs is to pass the gastro-intestinal 
tract due to its microenvironment (low pH, presence of digestive enzymes) [61]. These 
characteristics contribute to the elaboration of different systems such as the pH-sensitive NPs 
made with Eudragit® S100 enhancing intestinal absorption of the entrapped compound [70]. 
In the context of inflammatory bowel disease, ligands were grafted on poly(lactic-co-glycolic) 
acid-block-polyethyleneglycol (PLGA-PEG) to actively target the affected tissue [71]. PLGA-
PEG were also studied for the oral delivery of insulin avoiding thus parenteral administration 
[72] which may represent a quality-life improvement for patients. This is particularly crucial 
for the delivery of peptides. An alternative, especially in the case of cancer treatment is to use 
the lymphatic drainage to administer nanoparticulate drugs, the lymphatic system can be 
reached by parenteral (subcutaneous) route, but also through the oral mucosa or the 
respiratory tract. Local NP administration is thus an interesting alternative. Moreover, some 
organs are more easily accessible by another way than a systemic route. This is the case in the 
eyes where NP-loaded drugs or gene-delivery systems can be delivered by instillation into the 
conjunctival sac, intravitreous or subtenon injections of NPs that were set up for the treatment 
of eye diseases such as retinal neurodegeneration [73], glaucoma [74, 75], virus-infection [76] 
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or retinoblastoma [77]. Another example is the rectal administration that is used for colorectal 
cancer therapy purpose [78] but also for delivery of anti-vomiting drugs as an complement of 
chemotherapy [79]. The advantage of local administration is the limited area of action for 
highly active drugs. Thus, ocular administration of polymethylmetacrylate NP containing 
carboplatin, a chemotherapy drug with adverse side effects, allow a sustained-release of the 
drug in the vitreous and the retina without systemic detection of the drug for retinoblastoma 
treatment after a single subtenon injection [77]. Amongst local targets can be cited the inner 
ear [80] and hair follicles [81]. Following from that, whatever the administration route, nature, 
composition and building of the NP should be highly studied. The majority of the targeted 
ways (eyes, nose, lungs, gastrointestinal tract, cervico-vaginal) involves the crossing of a 
mucus barrier before internalisation of the NPs by the cells [82, 83]. In the case of local 
administration into the nose or the eyes, for example, the mucoadhesive properties of the NP 
must be high enough to enhance the retention time in the aim to extend the time of contact 
with the biological membranes to improve the drug absorption [84]. That is obtained playing 
mainly on the NP coating with surfactant molecules such as PEG, chitosan, lecithin which 
influences the pharmacological and chemical parameters characterizing the NPs [85-87]. In 
this way, Holden and colleagues have tested, using an ex vivo corneal model, PEGylated-
polyamidoamine dendrimers in situ-forming hydrogel for the delivery of timolol maleate and 
brimonidine for glaucoma treatment [88]. Then, it is noteworthy that the timing for drug 
action (short or long term action) will influence the choice as well as the stability of the NP 
encapsulated molecule. Hence, systemic administration through the nasal route is preferred 
when a rapid onset of the drug action is essential [67]. A meta-analysis of literature data 
concerning the clinical pharmacokinetics of three kinds of drugs dedicated to target the brain 
(opioids, benzodiazepines and anti-migraine) highlights differences between the formulations 
with a quicker effect when drugs are administered intravenously [89]. In the case of epilepsy-
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related convulsions, the rectal administration of diazepam leads to an effect within 15 to 20 
minutes after administering. In a rabbit model, the effect is visible as soon as 5 minutes after 
delivery of a submicron emulsion [90]. Finally, some administration pathways are 
preferentially studied for certain populations of patients such as young children or patients 
with neurological disorders. Thus, the rectal route is easier for paediatric patients whilst the 
nasal delivery is of interest for non-compliant patients suffering from cognitive disorders [59, 
90]. 
 For a systemic intervention, three routes are favored : parenteral, oral or nasal delivery 
[91]. In most cases, to increase the NP bioavailability and its stability, a coating is necessary; 
PEG or hydrophilic molecules with close properties are mainly used. In the case of a 
parenteral administration, the goal is to increase the life-time of the substance in the blood, to 
limit interaction with phagocytic cells or with proteins such as opsonins [92]. The mode of 
administration (i.e. intramuscular, intradermal) influences also the efficacy of the drug. A 
study shows the differential organ/cellular uptake of pluronic-stabilized poly(propilene 
sulfide) NPs in an in vivo murine model with a better efficacy for the intradermal injection 
upon an intramuscular one to reach lymph node, blood and spleen and immature and cross -
presenting antigen-presenting cells [93]. The development of stimuli-responsive NP is a 
promising way in therapeutics. Indeed, NP systemically delivered can be guided to the target 
site using physical properties conferred by surface functionalization of drug nanocarriers [92], 
limiting thus a dispersion through the body. Stimuli can be exogenously applied and can vary 
when a magnetic field, light or temperature is increased. Moreover, NP can be created in such 
a manner that they could be responsive to endogenous stimuli such as pH variation and 
activated by enzymes. The progress of technology allow even the building of multi-stimuli-
responsiveness drug delivery systems [92]. In this way, such a method was used in vivo by the 
way of MRI-guided focus ultrasound technology for enhancing brain delivery of 
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intravenously administered AuNPs. This method was then applied to visualize the tumor 
margin within xenografted animals by Raman spectroscopy [94, 95]. 
 
Diseases and therapy advances 
 Nanoparticles and neurodegenerative diseases 
ND are commonly late onset, progressive and fatal disorders of the central nervous system 
(CNS, the brain and spinal cord) leading to a neuronal loss in a specific brain area depending 
on the nature of the pathology associated with a neuroinflammation (microglial activation). 
This results in a gradual overcoming of cognitive and/or motor disabilities corresponding to 
the disease relative symptoms (phenotype). ND are currently affecting approximately 50 
million people worldwide. Alzheimer’s disease (AD) and Parkinson’s disease (PD), the most 
common ND with respective prevalence estimated to be more than 44.4 million in 2013 
(source: AD international) and 6 million people around the world [96-98]. Whatever the 
disease origin, i.e. familial or sporadic, ND are generally associated with aggregate-prone 
proteins accumulating in an insoluble form as cytoplasmic (tau, α-synuclein), extracellular (β-
amyloid peptide), or nuclear (ataxin) inclusions in or close to degenerating cells. Most of the 
resulting aggregates are highly ordered because they are enriched in crossed β-sheet structures 
(i.e. amyloid-like polymers) can be stained with dyes such as Congo red or Thioflavin T [99-
101]. It has been suggested that oligomeric species are the more toxic forms compared to 
larger aggregates [102]. Moreover, growing evidence is indicating that the spread of 
pathology is similar to prion-like form with an initial oligomer seeding event followed by the 
spread of the aggregates and a cell-to-cell communication of the pathology [100, 103, 104]. 
 Ageing is the common shared and essential risk factor associated to the appearance of 
such a kind of pathology [105]. Pathological proteins linked to genetically transmissible ND 
are natively mal-conformed constituting a constant risk throughout life [106]. In such a case, 
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the aggregation induction is a process linked to the time and to the risk factors relative to the 
concerned disease. For sporadic forms of ND, the involved proteins acquire their aggregate-
prone features mainly through covalent post-translational modifications such as oxidation, 
phosphorylation, nitration, or by proteolytic cleavage (for examples, see [107, 108]. 
Misfolding can induce either toxic gain-of-function or loss-of-function which can promote the 
oligomerization of pathological proteins. In all cases, the presence of aggregate-prone protein 
associated is challenging the proteostasis network (PN). Protein homeostasis (also called 
proteostasis, [109] depends on a network involving the cellular mechanisms dealing with 
protein from their synthesis to their elimination as well as nutritional status detection systems 
and quality control pathways [109-113]. Consequently, the proteostasis network (PN) 
corresponds to an integrated complex of sub-networks with different physiological roles 
linked by central master protein factors allowing coupled stress responses [114]. Mechanisms 
involved in the synthesis, quality control and protein degradation, the pathways linked to the 
energy sensing, metabolism regulation, stress response detection and response systems are 
counted among the PN. 
 Consequently, strategies to treat ND are targeting either the pathological protein 
downregulating their expression using gene therapy (Huntington disease (HD), Amyotrophic 
Lateral Sclerosis (ALS), familial PD) (reviewed in or activating pathways belonging to the 
proteostasis network [109, 115, 116] such as antioxidant machinery and activation of 
catabolic processes. 
 
Challenges for nanomedicine in the context of ND 
 Diagnosis and therapeutic strategies 
Except a post-mortem examination of the patient brain, in most of sporadic forms of ND, it is 
difficult to set up a definitive diagnosis. Nevertheless, using imagery techniques (positron 
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emission tomography (PET)or MRI) associated with the use of the appropriate tracer (such as 
in the case of AD or in PD context for example) allow the clinician to establish a probable 
diagnosis correlating neuroanatomy criterions with cognitive or motor deficiencies. For 
example, in the context of dementia of Alzheimer’s, the diagnosis criteria are based upon 
recommendation of the NINCDS-ADRDA (National Institute of Neurological and 
Communicative Disorders and Stroke - AD and Related Disorders association) [117] 
associating biological and clinical evidences for the establishment of a possible, a probable or 
definite AD diagnosis [97]. This evidence is brought by neurologic examination associated to 
morphologic (MRI), structural, functional or PET imaging and biochemical analysis by 
detection of biomarkers (Aβ peptide and total and/or phosphorylated tau) in the cerebrospinal 
fluid (CSF) but often, taken alone, this information is not sufficient for diagnosis. These 
techniques are useful and are more efficient in the assessment of the pathology at advanced 
stages of the disease. Indeed, ND are often characterized with a lengthy prodromal phase for 
the duration of which irreversible neuronal lesions are set up precedes cognitive and/or motor 
decline symptoms, this is the case for AD, PD, or ALS [118-120]. In the later, the first clinical 
signs appears when the motor neurons loss is over 50% [121]. Clinical trials for 
neurodegenerative targeting drugs are made with cohorts of symptomatic patients. Given that 
the existence of a long prodromal stage during which a compensation mechanism masks the 
neuronal degeneration that already took place, (as it is discussed in [103, 122]), it would be 
relevant to include patients at earlier phases of the disease. However, beyond the problem due 
to an extension of the trial duration - for example the AD prodromal phase was estimated to 
be an average of 9 years before the first cognitive symptoms detection [118] - is the problem 
of the cohort recruitment owing to while a huge progress in imaging techniques for ND 
diagnosis, it is still difficult to certainly asses the presence of the pathology and to name it. 
Furthermore, as the clinical trials in patients represent an important effort, there is no 
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satisfactory treatment as yet available to cope with NDs, only some drugs can alleviate the 
symptoms. 
 
 The blood-brain barrier: a shield too strong? 
Another major challenge is the particular status of the CNS due to the existence of the BBB, a 
protective neurovascular unit restricting the entry of the blood content into the brain and 
regulating nutriment and ion delivery to the brain tissue conferring it a privileged 
immunologic status (reviewed in [123, 124]). The BBB is a dynamic structure composed of 
brain microvasculature endothelial cells. They are characterized by specific tight junctions 
restricting paracellular diffusion and polarizing the structure, lacking fenestration and a 
minimal pinocytic activity. Whilst the endothelium is surrounded by pericytes, all embedded 
in a basal lamina and its extracellular matrix and all ensheathed by astrocytic end-feet [125-
127]. The BBB corresponds to a physical, metabolic and transport barrier segregating the 
brain blood flow from the rest of the organism.  
 Bypassing this complex and very selective shield is a critical point for the engineering 
of nanocarrier-based therapeutic strategies [128]. Only few small lipophilic molecules (< 
500Da) can diffuse freely through the BBB. Nutrients are transported across the BBB by 
specific transporters excluding or effluxing potentially neurotoxic molecules. The uptake of 
larger molecules (protein) such as iron transferrin or insulin is regulated via the highly 
specific receptor-mediated endocytosis. An adsorptive-mediated transcytosis, less specific is 
also described. The strategies for drug delivery to the brain should consider BBB permeability 
[127, 128]. Indeed, a systemic administration of a drug will not signify that it will enter the 
brain and while administration of higher doses which is related with more side effects (Fig. 3).  
 Consequently, the putative pharmacological approaches should consider the existence 
of this protective shield representing the main challenge in the treatment of brain affected 
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diseases. Two approaches are opposed for CNS drug delivery: invasive by breakage of the 
BBB (transcranial injection, ultrasound activated microbubbles, osmotic modulation of BBB 
permeability) or non-invasive delivery using small molecules, lipidation (prodrugs) or use of 
carrier-mediated transport [128]. Amongst the breakage methods, some, such as the use of 
ultrasound activated microbubbles are transient and reversible [95]. Consequently, the 
engineering of NP bypassing the BBB are promising tools for diagnosis and treatment, 
neuroprotection against ND as the image of the works of Kreuter and co-workers in 1995 who 
put in evidence the importance of use of surfactant coating (polysorbate 80 in this study) of 
drug-loaded NP to allow the passage of the BBB [129]. Finally, the drug driven to the brain 
through the BBB should not be rejected back by exchange channel at this level such as the 
efflux pump P-glycoprotein [130]. The last point to consider is the way of administration. 
Indeed, the ideal treatment should be easily administered to non-compliant patients who, due 
to the nature of their pathology i.e. a degenerative disease affecting the CNS, can present 
cognitive or psychiatric troubles. Hence, three major routes are privileged: systemic 
administration by oral or parenteral route on one hand and the intranasal route on the other 
hand (Fig. 3).  
 
Aims and strategies in the ND context 
 Diagnosis, theranostics and drug delivery: targeting the brain with 
NPs 
As presented above, the first challenge to consider in the ND context is to establish the 
diagnosis as earlier as possible. Some dyes are available to stain amyloid or amyloid-like 
structures such as a thioflavin T derivative, can cross the BBB, and the Pittsburgh compound 
B, used in PET-scan imaging [131]. However, for example for the case of AD, the amyloid 
burden is not well correlated with the cognitive decline but the cognitive decline is associated 
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with a decrease in the cortical thickness [103] and many efforts are made with the goal to 
develop diagnostic tools [132, 133]. It was also demonstrated that some healthy old people 
can have an extensive brain accumulation of Aβ peptide [134]. Moreover, a given aggregate-
prone protein is not exclusive for a given ND. Indeed, PD patients can present an Aβ 
accumulation. In addition, neurofibrillary tangles, constituted by aggregation of 
hyperphosphorylated tau, are not only an AD hallmark, but are characteristic pathological 
lesions in a group of diseases named tauopathies amongst them the fronto-temporal dementia 
or Pick disease [133, 135]. Consequently, ND diagnosis relies upon a body of evidence. 
Consequently, efforts are made in the aim to enhance the potency of diagnostic tools and to 
search for efficient biomarkers [136, 137]. 
 NPs are of a particular interest for the detection and imaging of amyloid-like protein 
species (imaging and radio-tracers) and in the assessment of the pathology presence. The NP 
will convey either antibody or dye recognizing the incriminated protein species or other 
significant target(s) [138]. Such NP can be ameliorated to present a therapeutic property, the 
term theranostic was coined to define such a technology. For example, the cyclophosphamide 
- a drug known to alleviate inflammation in cerebral amyloid angiopathy, which corresponds 
to the deposition of Aβ in the brain and leptomeninges small-to medium caliber blood vessel - 
was encapsulated into Magnevist ® - conjugated chitosan NPs that were also conjugated to an 
immunoglobulin F(Ab’)2 fragment against Aβ. These NPs play a dual role as a MRI contrast 
agent and at the same time as a nanocarrier for a drug [139]. 
 For drug delivery as highlighted here and in many reviews about brain drug delivery, 
the main thing to point out is that one must consider engineering NPs with the capacity to 
cross the BBB. This can be done by coupling the NP to a ligand such as transferrin, insulin, or 
an amino acid which have a high transport efficacy; agonist antibodies specific of receptors 
(OX26 that targets transferrin receptor); transporters (LAT-1 GLUT1 for amino acids) 
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involved in the regulation of molecule passage at this level [140-143]; or changing their 
lipophilicity or their surface potential by lipidization, or by surfactant coating [144]. For 
example the polysorbate 80 adsorbs ApoB and E lipoprotein in the blood which allow them to 
pass the brain capillary endothelial cells [142]. 
 
 Gene therapy 
Gene therapy strategies could be envisaged for the familial forms of ND. For example, 
familial forms of PD can be caused by mutation in the gene SNCA coding for the neuronal 
protein α-synuclein. Huntington disease (HD) is due to the repeat of a CAG motif in the gene 
coding for huntingtin. The strategy would be to silence such genes. In the case of PD [145], 
this therapeutic method can also be used to silence molecular targets thought to be involved in 
the pathogenic process. Thus BACE-1, a β-secretase participating in the maturation of 
amyloid peptide precursor (APP) into the Aβ peptide in the AD context, was down-regulated 
using QDs technology in the SK-N-SH cell line model [146].  
 
Therapeutic strategies using nanoparticles in ND 
 Alzheimer’s disease 
AD is the most common adult onset ND, affecting more than 35 million people worldwide. 
AD, widely characterized by two pathological hallmarks: formation of extracellular deposits 
of Aβ, senile plaques (SP) and intraneuronal accumulation of hyperphosphorylated tau as 
neurofibrillary tangles (NFT) or paired helical filaments (PHF) [147, 148]. Aβ results from 
the sequential cleavage of APP by the β- and γ-secretases. There are numerous drugs in the 
pipeline that are specific for AD but could also be used for other types of ND (Table 2). The 
current therapeutic strategies target aggregate formation to aid in the understanding of their 
involvement in AD pathogenesis. It is in the case of transferrin-PEG-QDs cross-linked to a 
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recombinant Aβ peptide in the goal to follow their oligomerization and evaluate the kinetics 
of fibril formation in vivo [149]. A similar approach tested in vitro used an Aβ monoclonal 
antibody coupled to near infrared fluorescent IONP as a potential theranostic technology 
[150]. Quantum dots coupled to anti-Aβ antibody were designed as lab-on-chip systems to 
allow the screening of potential anti-aggregating compounds in a micro-scale volume of body 
fluid [151]. Lab-on-chip devices using cadmium/selenide/zinc sulfide QDs in order to detect 
the plasma levels of ApoE ex vivo as a diagnosis biomarker [152]. Some other NP based 
systems were described for biomarker detection such as tau protein [153]. Superparamagnetic 
IONPs are widely tested for producing potent and specific contrast agents in MRI [154]. 
SPION coupled NPs were tested by in vitro imaging of Aβ-related aggregates [155] and in 
vivo with a transgenic AD mouse model [156-158]. This type of approach by coupling Aβ-
targeting antibodies to NPs give rise to the question of a double function of such nanocarriers 
which could have positive side-effect capturing toxic protein species, and activating 
elimination pathways adding a possible therapeutic action [159-161].  
 Disruption of amyloid aggregates using destabilizating drugs such as green-tea also 
known as polyphenol epigallocatechin gallate (EGCG) is extremely encouraging [162, 163] 
not only in AD but also in other ND such as PD. However, the bioavailability of EGCG and 
access to the brain is quite poor [99]. The integration of such a compound into NPs to enhance 
its delivery to the brain is logically studied [78] and appears to inhibit amyloid aggregates in 
vitro when incorporated to Tet-1 peptide (a neuron-targeting molecule allowing the bypass of 
the BBB via a retrograde axonal transport) linked selenium NPs [164]. The same strategy was 
chosen using sphingomyelin and cholesterol liposomes functionalized with amyloid-binding 
acidic lipids such as ganglioside GM-1, phosphatidic acid or cardiolipin in vitro and was 
shown to alleviate tau pathology acting on the balance between kinases and phosphatases 
while transposition to an animal model should take in account that GM-1 can cause 
Wilson et. al. 2014 
Review: ‘The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer’ 
 
21 
 
neuropathies [165]. Curcumin, which can bind amyloid aggregates, as EGCG (the both are 
actually in clinical trials for a possible AD therapeutic action) is also subjected to NP 
encapsulation in the aim to enhance its action as a proved PN enhancer compound since it 
presents a poor bioavailability in vivo [99, 166-169] not only in AD context but also in most 
of the degenerative diseases linked to protein aggregation such as type 2 diabetes [170]. 
Several kinds of NP were elaborated and tested in either in vitro or in vivo transgenic models; 
nanoliposomes [171-173], PEG-PLGA-NP [174, 175]. In the same way, in vitro experiments 
were conducted with PEG-PLGA NP containing selegiline [176]. 
 Polyphenols exert an antioxidant action presenting beneficial effects for 
neurodegeneration [177]. Thus, antioxidant drugs such as idebenone, an analogue of the co-
enzyme Q10 are in consideration for building anti-AD NPs [178]. Oxidative stress is a 
common feature of proteinopathies. Consequently, similar approaches consisting of the 
delivery of anti-oxidant molecules loaded NPs are elaborated in other ND context [78]. For 
example, pomegranate seed oil nanoemulsion was shown to delay the onset of prion 
pathology in a model of genetic Creutzfeld-Jakob disease [179]. 
 A deficit in the production of acetylcholine is related to AD [180]. Therapeutic 
strategies are targeting their efforts towards the inhibition of acetylcholinesterase or an 
agonist of cholinergic receptors [181] using molecules such as rivastigmine incorporated into 
liposomes [182, 183], or polymer [184] or galantamine [185]. This acetylcholine decrease was 
used as an in vivo biosensor system using carboxylated multi-walled CNTs and zirconium 
oxide NP onto which were co-immobilized acetylcholinesterase and choline oxidase and 
deposited on glassy carbon electrodes [186].  
 D-penicillamine, a copper chelating molecule, was shown to have an interest for AD-
targeted therapy [187, 188] since metal ions such as iron or copper are involved in the 
formation AD pathogenesis due to the binding of APP, their accumulation in the AD brain 
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[177, 189, 190]. This compound, already used in therapy of other pathologies such as the 
Wilson’s disease affecting the liver, rheumatoidis and lead poisoning was tested as a 
nanoformulation where it was covalently linked to NPs in vitro and was successfully shown to 
disaggregate Aβ peptide [191]. 
 
Parkinson’s disease, Amyotrophic lateral sclerosis and other 
neurodegenerative diseases 
PD, the second most common ND after AD. This pathology is characterized by α-synuclein 
aggregation, the physiological function of this protein still remains to be elucidated, and the 
specific degeneration of the dopaminergic neurons in substantia nigra, striatum and in other 
brainstem regions leading to the appearance of motor and cognitive clinical symptoms: 
bradykinesia, resting tremor, rigidity and other troubles. 
As for AD, most of the PD cases (90 to 95%) are from unknown etiology, however around 5-
10% of cases are familial forms due genetic mutations. There are 6 autosomal genes that are 
involved including SNCA encodes α-synuclein, LRKK2 (leucine-rich repeat kinase 2), PINK1 
or PARKIN were described [192-194]. Whatever the etiology of PD, modifications of α-
synuclein playing a major role in pathogenesis, the several NP kinds were elaborated prion-
like behaviour of this protein was assessed [100]. 
 Besides therapeutic strategies based on agent destabilizing protein aggregates, playing 
on the enhancement of the PN or targeting oxidative stress with the reformulation of the same 
molecules than used in AD therapy research, such as EGCG and curcumin [162, 195], the 
elaboration of PD specific therapeutic solutions consist in the enhancement of existing 
solutions which alleviates temporally the clinical symptoms - amongst them the oral 
administration of levodopa presents the highest efficiency on motor symptoms - and the gene-
based therapy [196]. Thus, new L-dopa formulation using NPs has been proposed: chitosan-
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coated NPs [197] and tested in vitro for toxicity [198]. An intrathecal implanted system 
allowing a site-specific controlled release of cellulose acetate phthalate NPs loaded with 
dopamine during a period of time was designed and evaluated in a rat model for the 
establishment of PD chronic drug delivery system [199]. Similarly, encapsulation of 
bromocriptin in NPs was also tested [200], but the finality of such approaches has especially 
an interest in the elaboration of effectiveness and non-invasive drug delivery systems 
targeting brain pathologies. Consequently, interest stays with the ability for nanosystems to 
deliver nucleic acid to lesioned cells for gene-based therapy [201], particularly regarding the 
advantages presented by NPs compared to viral vectors to date giving less immunogenicity, 
the possibility to repeat the treatment and most importantly their ability to cross the BBB. 
Nanogels composed of PEG and PEI covalent cross-linked were designed for oligonucleotide 
delivery. PEI derivatives are routinely used in mammalian cell culture transfection. The 
functionalization of such nanogels with insulin and transferrin allow them to reach the brain 
crossing the BBB [202]. They present the advantage of spontaneously encapsulating 
negatively charged oligonucleotides. Gene therapy can also involve the delivery of specific 
microRNA. In addition, some of these small oligoribonucleotides playing a role in the 
regulation of gene expression and can be deregulated in most of the neurodegenerative 
diseases [203, 204]. By this way, it is possible to silence defective genes in neurons [205] or 
to overexpress genes coding for proteins with a rehabilitating function i.e. therapeutic genes. 
Neurotrophins such as Glial cell line-derived neurotrophic factor (GDNF) or brain derived 
neurotrophic factor (BDNF) expression are in exploration for AD and PD, and was tested in 
the ALS context as a therapy for the repair of synaptic failure [206]. In vitro exogenous 
expression by vascular endothelial growth factor (VEGF) or GDNF overexpressing 
mesenchymal stem cells of GDNF had positive effects in an ALS rat model [207], GDNF 
expression has also a protective effect in a murine transgenic model for AD [208]. In a rat 
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model, it is possible using compact DNA NPs (naked DNA), directly injected into the brain to 
express a gene for a period of 8 weeks with minimal inflammation [209]. Promising results 
were obtained after transfection of cultured dopaminergic neurons using RTX-polyplex (PEI 
derivative) NPs as an in vitro model for PD [210].  
 ALS, (Motor Neuron Disease, Charcot’s disease, Lou Gerhing’s disease) is a 
devastating ND affecting motor neurons in the brain cortex, the spinal cord and the brainstem. 
It results in a progressive impairment of the motor functions (paralysis) until the death of the 
patient within 3 to 5 years generally by a respiratory failure as result of paralysis of the 
respiratory muscles. The pathology onset is generally around 60 years old and most of the 
cases are sporadic (etiology unknown). Approximately, 10% of ALS cases are of familial 
origin among them 20% due to a mutation in the gene encoding the Cu/Zn superoxide 
dismutase 1 (SOD1) [211, 212] and around 34% are due to a hexanucleotide expansion in 
C9ORF72 gene [213, 214]. C9ORF72 is also involved in the development of another ND, the 
fronto-temporal dementia which can be associated with ALS [215, 216]. Therapy using 
antisense oligonucleotides that target repeats containing related-RNA is a rational approach 
[217]. Besides a method for the oral deliver antisense oligoribonucleotides adsorbed onto a 
cationic core-shell NP has been described in a mouse model of the X-linked recessive 
Duchenne muscular dystrophy [218].  
 Huntington disease (HD) is a hereditary neurodegenerative disorder due to the repeat 
of a CAG motif in the gene coding for huntingtin. HD belongs to a group of proteinopathies 
due to such CAG (coding for glutamine) repeat in the mutated gene sequence. In this context, 
the elaboration of NP system are aimed either to modelize the pathology in vitro or in vivo by 
expressing a peptidic sequence containing a CAG repeat of a pathologic length with a strong 
tendency to aggregate and to cause cell degeneration on one hand. Hence, organic modified 
silica (or also called ORMOSIL) nanostructures permitted Klejbor and colleagues to express 
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the CAG repeat in rat or mouse brains through an intraventricular injection to modelize HD 
brain pathology [219]. Organically modified silica NPs are also of interest in targeting axonal 
transport defects in neurodegenerative condition [220]. Interestingly, it has been suggested 
that such particles are promising since by coupling them to protein allowing them to be 
specifically targeted to neurons and then to associate them to specific subcellular structures 
such as a molecular motor for intraneuronal transport [220]. On the other hand, amphiphilic β-
cyclodextrine oligosaccharide based molecules were successfully used as siRNA carriers to 
reduce Htt expression in rat striatum [221]. 
 NPs are apparent tools in neurodegenerative diseases treatment but the arising 
technology in this domain is biological nanovesicles or exosome-mediated therapy [222, 223]. 
Exosomes are believed to participate in cell-to-cell communication, were shown to naturally 
convey protein or nucleic acid to receptor cells (discussed in further detail in extracellular 
vesicles section). Since these vesicles are produced by most cells, not surprisingly neurons, 
glial and microglial cells produce exosomes. The elegant work of Alvarez-Erviti and 
colleagues present a safe tissue-specific siRNA delivery (brain and muscle) by engineered 
exosomes from the transfection of exosome producing cells with a gene for the expression 
fusion endosomal protein (LAMP2b fused to a brain or muscle peptide), to their 
administration by intravenous injection after their electroporation-mediated loading of siRNA. 
The high efficiency of this system to knockdown the targeting gene is very promising 
especially as a siRNA against BACE-1 was used in normal and AD modelizing mice [224], 
discussed in [225]. However, exosomes produced in a pathological condition by themselves 
could be a new therapeutic target since they were suggested to participate in cell-to-cell 
transmission of prion-like aggregate-prone proteins and in degeneration progression in AD 
and PD [100, 226]. Microvesicles were shown to contribute to the microglial activation, 
induction of inflammation and to participate in neurodegeneration [227]. 
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Neurodegenerative disorders as a consequence of an exposure to 
nanoparticles 
Owing to the BBB protective function, it can be difficult to specifically target molecules to 
the brain parenchyma hence the multi-functionalization is necessary for brain targeting NP. 
However, as an intrinsic function of the BBB is to avoid the penetration of potential harmful 
molecules into the brain tissue. Consequently, neurotoxicity of NP needs to be considered for 
the same reasons than a more conventional therapeutic system. Since microglial activation is 
involved in the neurodegenerative pathogenic process in a majority of CNS disorders, it is one 
of the most important points to consider and to envisage in NP neurotoxicity. In this way, an 
in vitro study using cultured microglial cells has shown that amongst four types of inorganic 
NPs, TiO2, SiO2, Fe3O4, and hydroxyapatite, while Fe3O4/hydroxyapatite (also known as 
HAP) and TiO2 presented the ability to trigger the expression of inflammation related iNOS 
(inducible nitric oxide synthase) and activate NF-κB signaling pathway, all the tested NP 
induces to a variable extent the increase of pro-inflammatory molecule production (TNFα, IL-
1β and IL6) which lead to a toxicity in PC12 cells [228]. Another study using IONPs, in vivo 
and in vitro show that activation of the microglial cells and possible pathological changes as 
reflected by morphological changes in the olfactory bulb, striatum and hippocampus. 
However, while the activation of microglial cells reflected by production of reactive oxygen 
species and nitrogen oxide is assessed, it remains to be seen if it is in favour of 
neuroprotection or neurotoxicity since microglial cells represent the immune system in the 
brain tissue [229]. SiO2 NPs were shown to induce PD’s like pathology in Zebra fish [230]. 
Other studies regarding the toxicity for medical purpose of magnetic NPs in an in vivo rat 
model show nearly no toxicity [231]. Another study concerning the toxicity of aminosilane-
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coated IONPs in three cultured cell models conclude on a satisfying safety regarding the 
concentration used while a differential charge sensitivity of primary cultured neurons when 
compared to astrocytes with a higher dosage [232]. Taken altogether these data are giving rise 
to the concern of side effects linked to the pharmaceutical use of NPs. The risk is to taken into 
account keeping in mind the benefits provided by NPs. The differential side effects of NPs 
depends upon the considered organ as well as the model used in the studies i.e. in vivo or in 
vitro model. Consequently, as for each active biological compounds, the use of NPs in human 
medicine should be carefully thought out considering the route of administration which well 
engages different organs, the dose, but also the benefits for the patients and the exposure time. 
At the same time, the risk to formulate self-evidence fact, toxicity of NPs, for human and 
other purpose should be carefully studied for the long term.  
 
 Cancer 
The formation and the development of a tumor is a process of several steps since the cellular 
transformation following the passage with the acquisition of different properties from a 
normal to tumoral cell. Successive genetic alterations are at the origin of the cellular 
transformation process and at the present time we are not able to establish exactly the 
mutation(s) or genetic segregation necessary to explain the transformation event. It was 
proposed by Hanahan and Weinberg that the transformation depends upon acquisition of 
different intrinsic properties, the hallmarks of cancer, or by diverse attacks like metabolic or 
oxidizing stress allows DNA damage and genomic instability [233, 234]. The order by which 
cells acquire their properties seems to depend on the type of cancer and the cellular type. 
Furthermore, the identification of genetic variability within the same tumor or regional 
differences by self-production of growth factors highlights the heterogeneity of the tumor. 
Neoplastic lesion development implies the clearing of anatomical barriers. The cancer cells 
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invade the stoma through proteolytic enzymes where the presence of cancer cells can initiate 
several events to support tumor progression [235, 236]. The orchestration of this process with 
the anarchic cellular proliferation and a weak pressure in oxygen induces hypoxic stress (Fig. 
5). In this microenvironment which becomes hostile for both healthy and cancer cells, the 
cells respond by the induction of a neo-angiogenesis [237]. The VEGF, produced by cancer 
cells is released into the tumoral matrix, it activates the formation of new blood and lymphatic 
vessels from the cells of the vascular or lymphatic endothelium respectively who express the 
VEGF receptor (VEGFR) [238]. The fixation of VEGF on its receptor stimulates migration 
and proliferation in endothelial cells and the permeability of capillaries. This enables three 
parameters - oxygen, nutriments and elimination of waste - are restored, leading to a 
supplementary delay for the tumoral cells. These changes have involved the recruitment of 
fibroblast, migration of immune cells, matrix remodelling and development of vascular 
networks. In this context we can evaluate a tumor as a complete organ as opposed to simply 
visualising a mass of cells. The tumor topography is continually being remodelled where the 
vasculature network limits the outgrowth. By consequence, the tumor seems accessible by 
blood vessels and systemic treatment. Unfortunately, the vascularization process is imperfect, 
hypoxic and anoxic areas appear, pulling a pressure of selection and the appearance of highly 
aggressive cells (Fig. 5). Gradually, the tumoral cells penetrate into the blood and lymphatic 
vessels and colonize the secondary organs via metastasis [239]. The conventional methods 
used in cancer therapy, chemotherapy, radiotherapy and surgery are limited with the 
appearance of resistant cells or by the access to the cancer cells themselves in the tissue 
invaded. The neoplastic lesions impairs the systemic drug delivery both by the remodelling of 
the vascular network and by the chemical properties of the tumor microenvironment such as 
acidic, inflammatory area, or in the presence of healthy cells perturbing the drug properties 
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and subsequently the efficiency. Taken together, the drug concentration in the tumoral site is 
suboptimal and induces several toxic effects in normal cells.  
Oral or systemic drug delivery offers a different mechanism to reach the cancer cells 
and also at the same time reducing the toxicity effects on healthy tissue. Nevertheless, 
targeting the drug to the correct site and thus, avoiding the side effects or creating resistance is 
a great challenge to nanomedicine. During the last 30 years, the idea of using NPs as a vehicle 
to transport drugs seems to be a great candidate and improves the quality of life of patients. 
For example, Doxorubicin can be used to treat a range of cancers but it is highly toxic and 
induces heart problems. Whereas Doxil, the first success in nanomedicine as a drug carrier 
reduces the toxicity effects of free Doxorubicin in the heart [2, 12, 240-242]. Doxil is a lipid 
bubble (liposome) of 100 nm in diameter engineered by self-collapse around the drug. The 
size of this liposome offers an opportunity to access the tumoral vascular network whilst 
escaping the healthy vessels. To help the Doxil to evade the immune system or engulfment by 
liver cells, PEG was used to coat the lipid surface. The Doxil liposomes facilitate them to 
accumulate in the tumor, the surface of the liposome degrades, releasing the drug from its 
carrier and attacks nearby cells. The first step in drug discovery was established, the survival 
rate of patients and the quality of life were improved but like every original works, few 
questions still remain such as how to maintain and target specifically the cancer cells. The 
challenge was to find the component to carry the drugs, their size and the manner to deliver 
the active substances. The Doxil was the base of the nanoparticle design with a spherical form 
and membrane-coated. Larger particles impaired the access to the different parts of the tumor 
independently of their own entry in the tumor vascular fenestrae which could be a block and 
induce a clearance of the NPs. Furthermore, some types of cancer such as pancreatic and 
breast cancer are enriched in collagen which represents a physical barrier for drugs. The range 
of nanoparticle size is between 30 to 100 nm in diameter. The tumor angiogenesis vessels are 
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disorganized and leaky but NPs with more than 100 nm diameter fail to enter and deliver their 
material. Different companies have engineered microspheres specific to target cancer cells. 
The company BIND Biosciences have developed the BIND-014 a Docetaxel polymer 
nanocarrier directed against both primary and metastatic prostate cancer cells by binding to 
prostate-specific membrane antigen (PSMA) [243] (Table 3). BIND-014 has currently entered 
phase II clinical trials, specifically targets the PSMA which is a transmembrane glycoprotein 
(known also as Nacetyl- L-aspartyl-L-glutamate peptidase I and glutamate carboxypeptidase 
II) predominantly expressed on prostate cancer cells. Nowadays, some polymers are added at 
the membrane to target some biomarkers found at the cancer cell surface and to facilitate the 
drug delivery. Development of personalized therapy against oncogene(s) involved in 
proliferation and survival pathways represent a new insight in cancer therapy. Many 
oncogenes are abnormally activated in cancer cells. The epidermal growth factor receptor 
(EGFR) is the most common oncoreceptor deregulated in cancer. Two compounds designed 
against mutated EGFR, gefitinib and erlotinib used for the treatment of non-small lung cancer 
decrease tumor size and subsequently the survival rate of the patient. Unfortunately, the 
outcome of the patient still remains poor, apparition of new EGFR mutations impaired the 
drug efficiency and increased the number of resistant cells [244]. By consequence, therapeutic 
agents designed for one target are not really efficient against a multifactorial disease like 
cancer. Essentially, few compounds against multiple targets are designed, with predominantly 
the Single Drug Inhibitor (SDI) or Multi Drug Inhibitor (MDI) to inhibit cancer cell growth 
and survival. The SDIs affects multiple pathways simultaneously whereas the MDI are a mix 
of drugs to inhibit multiple pathways. These approaches seem better to avoid drug resistance 
that are observed and to minimize the side effects. Both types of SDI and MDI have pros and 
cons, however they both share the same problem of how to overcome delivery and 
accumulation at the tumor site. The combination therapies available today are limited due to 
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different drugs have different properties such as pharmacokinetics, biodistribution and 
transport which cause problems in the dosing and optimization [245-248]. These challenges 
have been the driving power to test out various ways to deliver multiple drugs within one 
single nanoparticle [249, 250]. The particle size is a major factor affecting nanoparticle 
toxicity and the success of MDIs. As such if the particles are too small (i.e. <10 nm), they are 
able to pass the BBB causing damage or if they too large (i.e. >100 nm) they could be 
inefficient as carriers [251] Owing to the heterogeneity nature of cancer cells within the same 
tumor, and multitude of possibilities for both oncogene and survival pathways abnormally 
activate the method by which could be optimized the MDI represent the new age of 
personalized treatments. The ambition of nanoparticle-based therapy is to deliver multiple 
drugs whilst addressing the specificity and optimization of pharmacokinetics [252, 253].  
There are currently only a few nanomedicines using NPs approved currently for the 
use in the cancer treatment such as Abraxane® (Celgene Corporation, Inc., Berkeley Heights, 
USA), Doxil® (Janssen Biotech Inc., USA), Depocyt® (Pacira Pharmaceuticals Inc., San 
Diego, CA, USA), Myocet® (Sopherion Therapeutics Inc., USA), DaunoXome® (Galen US 
Inc., USA), Oncaspar® (Enzon Pharmaceuticals Inc., Bridgewater, USA) and Genexol-PM® 
(Samyang Biopharmaceuticals Corporation, Korea) (Table 3). There are a number of NPs that 
are entering early clinical trials or are in the pipeline (Table 3). Although the clinical potential 
of these NPs in nanomedicine, there still remains limitations with the technology regarding 
the difficulties experienced in the manufacturing and the hurdles faced in stimuli responsive 
drug delivery release. The success and development of these NPs to be used in nanomedicine 
will depend upon all the factors already discussed such as the physical properties of the NP, 
targeting to specific tissues/organ/cells, bioavailability, and survival rate of the patients. The 
challenge for the future will be to develop intelligent NPs personalized for each patient for 
routine use in the clinic practice.  
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Extracellular vesicles (EV) 
Nanovesicles (also called EV) are small parcels that allow information to be transferred from 
one cell to the next. These vesicles form a communication network in the body between 
neighbouring cells and distal sites. They were first reported more than 30 years ago by Trams 
et al in 1981 to result from exfoliation of the plasma membrane from neoplastic cell lines 
[254]. These vesicles were shown to contain membrane bound enzymes which could be taken 
up by recipient cells When they observed the vesicles under electron microscopy, there was a 
mixed population containing vesicles ranging from the smallest at 40 nm to 1000 nm [254]. 
The smallest vesicles ranging in size from 40 nm to 100 nm are now known as exosomes. 
These small vesicles were believed to be part of the cells garbage disposal system removing 
obsolete membrane and cytosolic proteins such as in reticulocyte maturation [255]. In more 
recent years, exosomes have been shown to play key roles intercellular signalling, for 
example, in immune system functions such as in antigen presentation of T cells [256], in 
immune rejection of murine tumors [257] and in the activation of both B and T cell 
proliferation [258]. It is more commonly accepted that vesicle secretion occurs from most cell 
types if not all. There are three main populations of EVs that have been characterised which 
depend on their intracellular origin. The properties of EVs and the ability of the vesicles to 
deliver their content to a recipient are similar to liposomes that can be packed with therapeutic 
molecules. These vesicles could be used both as mediators of tumor resistance and as vehicles 
for targeted drug delivery.  
Natural EVs consist of exosomes, ectosomes, microvesicles, oncosomes, and shedding 
bodies (apoptotic bodies) ranging in size from 30 to 1000 nm [259]. Exosomes are derived 
from the inward budding of the late endosome and hence have a similar lipid biolayer 
composition to the plasma membrane of the origin cell. Exosomes are maintained in the cell 
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within the multivesicular bodies (MVBs) and potentially have two fates in the secretory 
pathway, degradation by fusing of the MVB with the lysosome or release at the plasma 
membrane from the cell [260]. Exosomes can be identified in combination of specific protein 
markers for MVB such as for example, Cluster of Differentiation 63, ALG-2-interacting 
protein, and Tumor susceptibility gene 101, according to their size (30–100 nm), morphology 
(saucer shape is observed after fixation under transmission electron microscopy), and their 
density (1.15–1.19 g/ml in sucrose) [261]. It is now clear that it is difficult to distinguish 
exosomes from other subtypes using the current methods [262-264]. It remains a challenge to 
develop more sensitive methodologies to clearly define and separate the EV subtypes.  
 
The natural alternative 
Exosomes play a major role in many biological processes. They are vehicles that carry both 
genetic and proteomic information, and hence are presumed to play a role in cell-to-cell 
communication. The discovery that exosomes have the ability to transfer biological material 
such as proteins, mRNA and miRNA to other cells, opened up the prospect that exosomes 
could be utilised as vehicles to transport small molecule compounds in the body [265-267]. 
The ability to alter protein expression through RNA interference (RNAi) has grown with 
interest in respect with the applications to treat various diseases. However, a number of 
problems are encountered such as efficiently targeting specific tissues, preventing an immune 
response and toxicity [225]. Current research for the clinical application of RNAi focuses on 
three types of delivery: viruses, polymer-based NPs and liposomes. Nevertheless, there are a 
number of caveats that limit the use of these types of carriers. Viral particles are easily 
removed from the bloodstream via antibodies and can elicit an immune response by activation 
of complement or coagulation factors [268]. Polymer-RNA complexes can be protected from 
degradation in the bloodstream but can accumulate in other types of tissues including the 
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kidney, lung, liver, and spleen and thus perhaps limiting their access to the target tissue. 
Liposomes can adsorb opsonins that in turn can elicit an immune response leading to 
phagocytosis due their net charge and size [269]. The natural alternative to all these carriers 
would be to harness the body’s own delivery system- ‘exosomes’ which would bypass the 
problems concerning immune response, targeting, and biodegradation of cargo molecules. In 
a first study of using exosomes as vehicle carriers from immature murine dendritic cells to 
deliver a small-molecule, anti-inflammatory drug to immune cells [267]. Proof of principal 
was established when Alvarez-Erviti and colleagues harvested modified exosomes from 
dendritic cells and expressed a fusion protein of LAMP2B and a neuron peptide [224]. The 
siRNA for BACE1 (a protease implicated in AD) was then electroporated into the exosomes 
and intravenously injected into mouse brain. The results were promising as siRNA for 
BACE1 delivered by exosomes could efficiently knockdown BACE1 levels in the mouse 
brain. However, the use of this technology in the clinical situation still has a number of 
drawbacks. Firstly, the techniques used for the characterization and purification of exosomes 
need to be addressed as some exosomal markers are observed in other types of vesicles [270]. 
The second is to address the methods used to load exosomes with siRNA need to be 
optimized to increase the efficiency and decrease the large amounts of exosomes administered 
during therapy. Thirdly, the targeting of exosomes to specific tissues and transport across the 
BBB needs to be improved. Once we discover how RNA is packaged into exosomes this will 
revolutionize RNAi-mediated therapy. There are several schools of thought of how RNA 
(miRNA and mRNA) is encapsulated into exosomes, the most obvious is that the RNA is 
derived from the cytoplasm due to an invagination event at the MVB into ILVs. In fact, 
inconsistences remain in the field, some studies have reported that exosomes have small 
amounts of 18S and 28S RNA; that not all exosomes contain mRNA and miRNA; and whilst 
others have shown that little of the mRNA and miRNA is specifically targeted and loaded into 
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the exosomes [265, 271-274]. These differences observed may reflect the cell type, dependent 
upon cell homeostasis, the stage of the cell cycle or due to stress conditions. Nevertheless, 
these studies indicate that miRNA and mRNA incorporated into ILVs is a regulated process. 
Exosomes are comparable to liposomes as they have the ability to cross the BBB, allowing 
them to be ideal carrier vehicles [275]. A number of studies have shown that exosome 
signature found in glioblastoma patients showed a high level of TGF-band tumor antigen 
EGFRvIII [275-277]. As the identity of exosomes depends on the cell type, exosomes could 
be primed to carry biological or chemical agents. Altogether, exosomes appear to be potential 
therapeutic carriers that would aid in the treatment of a number of devastating human diseases 
from neurodegeneration to cancer.  
 
Conclusion 
The nanotechnology approaches of drug targeting include an array of NPs that have been 
designed for localised or sustained-controlled release discussed within this review and 
elsewhere [2, 15, 278-280]. Most of these technological advances have brought products from 
the bench to bedside but the benefits to the patient have been slow and extend the patient’s 
life by only a few months in some cases. In the past, the use of NPs was visualized as a 
competitive platform for the drug delivery. Nevertheless, nanotechnology has pros and cons 
(Fig. 6) which is constrained by many factors such as size, surface chemistry, shape/geometry, 
targeting ligands of NPs etc. The emergence of using exosomes in nanomedicine as a natural 
drug delivery vehicle is a promising idea. Since exosomes carry many of the desirable 
attributes of liposomes i.e. the attributes to transport hydrophobic drugs on the surface of the 
membrane and hydrophilic drugs in the liquid core. Whilst NPs might initiate an immune 
response, exosomes are less likely to elicit an immune attack and cellular toxicity. The major 
challenges will be to understand and to develop exosome-based drug delivery vehicles 
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without affecting the physical properties and producing reproducible exosomes that are 
biologically active in the treatment of human disease from neurodegeneration to cancer. 
 
 
Figure legends 
Figure 1 Nanotechnology evolution- the number of publications per year. Publication in 
the area of Nanoparticles/Nanomedicine is experiencing exponential growth over the last 15 
years. These are the number of annual publications with keywords “Liposomes”, 
“Nanoparticles” “Nanoparticles and drug metabolism”, and “Liposomes and drug 
metabolism” between 1965 and 2014 in Pubmed. 
 
Figure 2 A. Types of nanoparticle in drug delivery. Schematic showing the structural 
variation between various nanoparticles (NPs), such as solid lipid NPs, liposomes, polymeric 
NPs, gold NPs, carbon nanotubes, dendrimers, quantum dots, iron oxide NPs, cerium oxide 
NPs, and nanogels. B. Physical properties of nanoparticles. Schematic showing the 
composition, surface chemistry, targeting ligands and physical properties are all important in 
nanoparticle design. 
 
Figure 3 Nanoparticle- mode of delivery. The various sites in the body used for nanoparticle 
delivery. In bold are indicated the site of administration, normal font corresponds to the 
pharmaceutical forms that can be used and italic to the targeted pathologies and/or the extent 
of the delivery. 
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Figure 4 BBB challenge for neurodegeneration. The strategies employed in optimising the 
engineering of nanoparticles to bypass the BBB (in italic). In bold, represented by the 
different BBB components (see the text). 
 
Figure 5 Spatial relationships of O2 levels between the blood vessel and a malignant 
tumor. In normoxic conditions, defined where oxygen concentrations are above 5%, present 
in areas less than 70 µM from the tumor blood vessels. The normoxic areas near the blood 
vessels are accessible by chemotherapy treatment whilst areas deeper into the tumor are 
inaccessible. In hypoxic conditions defined by oxygen concentration lower than 0.5%, present 
at a distance more than 100 µM from the tumor blood vessels. In these areas, O2 
concentrations are reduced, thus creating a hypoxic area within the tumor microenvironment. 
These areas are reachable by nanoparticle treatment. 
 
Figure 6 Perspective model. Schema shows the pros and cons of nanotechnology using 
nanoparticles versus exosomes in the treatment of neurodegeneration and cancer. 
 
Table 1 Types of nanoparticles and their potential uses in nanomedicine. 
 
Table 2 Drugs approved or in the pipeline for ND. 
 
Table 3 Nanoparticles approved or in clinical trials for cancer therapy 
 
List of abbreviations: 
Aβ, β-amyloid peptide; AD, Alzheimer’s disease; ALS, Amyotrophic Lateral Sclerosis; APP, 
amyloid precursor protein; AuNPs, gold nanoparticles; BACE-1, beta secretase-1; BBB, 
Wilson et. al. 2014 
Review: ‘The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer’ 
 
38 
 
blood brain barrier; CNT, carbon nanotube; CNS, central nervous system; CONP, cerium 
oxide nanoparticle; EGCG, epigallocatechin gallate; EGFR, epidermal growth factor; EV, 
extracellular vesicle; GDNF, Glial cell line-derived neurotrophic factor; IONP, iron oxide 
nanoparticle; MDI, multi-drug inhibitor; MRI, magnetic resonance imaging; MVB, 
multivesicular body; ND, neurodegenerative diseases; NP, nanoparticle; PD, Parkinson’s 
disease; PEG, polyethylene glycol; PEI, polyethyleneimine; PET, positron emission 
tomography; PLGA, poly(lactic-co-glycolic) acid; PN, proteostasis network; PNP, polymer 
nanoparticle; QD, quantum dot; RNAi, RNA interference; SDI, single drug inhibitor; siRNA, 
small interfering RNA; SLN, solid lipid nanoparticle; VEGF, vascular endothelial growth 
factor. 
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Table 1 Types of nanoparticles and their potential uses in nanomedicine 
 
Type of nanoparticle Size range (nm) Therapy/Disease Reference 
Solid lipid NPs 50-1000 ALS, AD, HD, various cancers (281-285) 
Liposomes 25-205 AD, Kaposi sarcoma, breast 
cancer, melanoma 
(173, 286-290)  
Polymeric NPs 10-100 Cancer, Poly Q (219, 291)  
Gold NPs 4-40 Cancer (292-295)  
Quantum dots 3-30 Cancer, ND (24, 296)  
Carbon nanotubes 0.4-3 (d) x 20-1000 (l) Cancer, AD, (297-301)  
Dendrimers 2-10 Breast and colon cancer, Prion (302-305)  
Iron oxide NPs 5-200 AD, ALS (306-308)  
Cerium oxide NPs 5-400 AD, cancer (309, 310)  
Mesoporous silica NPs 30-280 Cancer (311-315) 
nano-Hydroxyapatite 2.5-200 Cancer (52-54) 
Nanogels 20-200 Melanoma, breast and 
pancreatic cancer, ND 
(56, 88, 316, 317)  
 
